Epidemic Status of Acinetobacter ssp. in Lower Respiratory Tract Infection and Their Drug Resistance
- VernacularTitle:下呼吸道感染不动杆菌属流行及耐药现状分析
- Author:
Yanli WANG
;
Mao HUANG
;
Yaning MEI
;
Hao LIU
- Publication Type:Journal Article
- Keywords:
Lower respiratory tract;
Infection;
Acinetobacter;
Resistance
- From:
Chinese Journal of Nosocomiology
2009;0(13):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the epidemic situation of Acinetobacter in lower respiratory tract infection and their drug resistance,in order to provide evidence for clinical anti-infection therapy. METHODS The data of Acinetobacter from the sputum specimens of inpatients in our hospital with lower respiratory tract infection during 2006-2007 were collected and analyzed with the software the software WHONET5.4. RESULTS Among all pathogens in lower respiratory tract infection,Acinetobacter accounted for 9.2% in 2006 and 7.4% in 2007,the rate in deparment of neurosurgery,surgical ICU and respiratory ICU was higher. Acinetobacter had the highest susceptible rate to imipenem and were also susceptible to meropenem and cefoperazone/sulbactam. However,Acinetobacter had higher resistant rate to imipenem and meropenem while higher susceptible rate to cefoperazone/sulbactam in 2007 than in 2006. The susceptible rate of Acinetobacter to the third and forth generation cephalosporins,amikacin,levofloxacin and aztreonam was lower than 50%. CONCLUSIONS The drug resistance mechanism of Acinetobacter is so complicated that many kinds of drugs prove poorly effective. Carbopenems are recommended when single drug is utilized and drug combination based on the clinical and laboratory information can be tried.
